Two studies evaluating the efficacy and long-term safety of the inhalable, rapid-acting dry powder insulin formulation (Exubera, Pfizer/Aventis) demonstrate that the drug was able to sustain glycemic control and pulmonary function in patients with type 2 diabetes

Get the latest industry news, event updates, and more from Managed healthcare Executive.

Subscribe Now!

Glycemic control and pulmonary function sustained throughout long-term use of inhalable insulin

Newsletter